Cachexia in Pancreatic Neuroendocrine Tumors: A Comparison with Pancreatic Adenocarcinoma Abstract #521

Introduction: Patients with pancreatic cancer (pCA) have a high propensity for cachexia even in the absence of metastases. On the other hand, patients with pancreatic neuroendocrine tumors (pNET) often maintain their weight and muscle mass for a long period of time even with liver metastases.
Aim(s): We undertook a study to compare the magnitude of cachexia in patients with pNET and pCA.
Materials and methods: We screened our clinical nutrition database and identified patients with pNET and pCA who had full nutritional work up with subjective global assessment scores (SGA), and body mass index (BMI). Cachexia was defined as SGC=C and or BMI<18.5 Kg/M2. The pNET were compared with pCA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Amit Yelsangikar

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Erin Laing
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#2697 Telephonic Communication in Palliative Care for Better Management of Terminal Cancer Patients in Rural India - A NGO Based Approach
Introduction: Due to financial incapability and absence of manpower poor families often fail to carry their advanced cancer patients to the nodal centres.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Nabanita Mandal
Authors: Mandal N, ...
Keywords: cancer
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd